KR20010057429A - Skin care composition containing Ursolic acid - Google Patents
Skin care composition containing Ursolic acid Download PDFInfo
- Publication number
- KR20010057429A KR20010057429A KR1019990060763A KR19990060763A KR20010057429A KR 20010057429 A KR20010057429 A KR 20010057429A KR 1019990060763 A KR1019990060763 A KR 1019990060763A KR 19990060763 A KR19990060763 A KR 19990060763A KR 20010057429 A KR20010057429 A KR 20010057429A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- retinol
- ursolic acid
- subject
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 title claims abstract description 42
- 229940096998 ursolic acid Drugs 0.000 title claims abstract description 38
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 124
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 63
- 229960003471 retinol Drugs 0.000 claims abstract description 61
- 235000020944 retinol Nutrition 0.000 claims abstract description 61
- 239000011607 retinol Substances 0.000 claims abstract description 61
- 239000002537 cosmetic Substances 0.000 claims abstract description 48
- 239000002253 acid Substances 0.000 claims description 9
- 230000006872 improvement Effects 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 30
- 239000008406 cosmetic ingredient Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 50
- 230000037303 wrinkles Effects 0.000 description 44
- 230000000052 comparative effect Effects 0.000 description 32
- 238000012360 testing method Methods 0.000 description 32
- 230000037394 skin elasticity Effects 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 206010040880 Skin irritation Diseases 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 238000002845 discoloration Methods 0.000 description 9
- 230000036556 skin irritation Effects 0.000 description 9
- 231100000475 skin irritation Toxicity 0.000 description 9
- 230000007794 irritation Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 230000002335 preservative effect Effects 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 206010051246 Photodermatosis Diseases 0.000 description 6
- 230000007012 clinical effect Effects 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- 230000008845 photoaging Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 229940113124 polysorbate 60 Drugs 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 4
- 238000011076 safety test Methods 0.000 description 4
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 231100000344 non-irritating Toxicity 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- -1 retinol Chemical compound 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000036572 transepidermal water loss Effects 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 229940124558 contraceptive agent Drugs 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 235000010389 delta-tocopherol Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000020945 retinal Nutrition 0.000 description 2
- 239000011604 retinal Substances 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 229960000342 retinol acetate Drugs 0.000 description 2
- 235000019173 retinyl acetate Nutrition 0.000 description 2
- 239000011770 retinyl acetate Substances 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 239000002446 δ-tocopherol Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241001481760 Erethizon dorsatum Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000000979 Erythema Induratum Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000034874 Product colour issue Diseases 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- XJKITIOIYQCXQR-SCUNHAKFSA-N all-trans-retinyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C XJKITIOIYQCXQR-SCUNHAKFSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940079894 benzophenone-9 Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000021019 cranberries Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004141 dimensional analysis Methods 0.000 description 1
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- CBKLICUQYUTWQL-XWGBWKJCSA-N methyl (3s,4r)-3-methyl-1-(2-phenylethyl)-4-(n-propanoylanilino)piperidine-4-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.CCC(=O)N([C@]1([C@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 CBKLICUQYUTWQL-XWGBWKJCSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 150000002966 pentacyclic triterpenoids Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229940071220 retinyl linoleate Drugs 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 기존의 화장료 성분인 레티놀(Retinol)과 함께 우솔릭산(Ursolic acid)을 함유하는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing ursolic acid together with retinol, which is an existing cosmetic ingredient.
본 발명의 화장료 조성물은 우솔릭산을 함유함으로써 레티놀의 피부개선 효과를 현저하게 향상시키고, 레티놀이 함유된 화장료가 가지고 있는 안전성(safety) 및 안정성(stability) 문제를 해결할 수 있었다.The cosmetic composition of the present invention can significantly improve the skin improvement effect of retinol by containing ursolic acid, and solve the safety and stability problems of the cosmetics containing retinol.
본 발명의 화장료 조성물에서 레티놀은 화장료 총중량에 대하여 0.001∼10.0중량%, 바람직하게는 0.05∼2.0중량%의 양으로 함유되며, 우솔릭산(Ursolic acid)은 화장료 총중량에 대하여 0.01∼5.0중량%, 바람직하게는 0.1∼2.0 중량%의 양으로 함유된다.In the cosmetic composition of the present invention, the retinol is contained in an amount of 0.001 to 10.0% by weight, preferably 0.05 to 2.0% by weight, and ursolic acid is 0.01 to 5.0% by weight, based on the total weight of the cosmetic. Preferably in an amount of 0.1 to 2.0% by weight.
Description
본 발명은 레티놀과 함께 우솔릭산(Ursolic acid)을 함유하는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing ursolic acid together with retinol.
대부분 사람들의 경우 성장기에는 일광에 대하여 피부가 쉽게 대응을 하지만, 연령이 높아짐에 따라 피부조직이 점차 변화하면서 일광에 쉽게 대응하지 못하게 됨으로써 주름살, 피부의 두꺼워짐, 피부의 처짐, 피부 탄력의 상실, 피부의 거칠어짐, 피부의 건조함, 피부얼룩 등의 증상이 생기게 되는데, 일광에 의한 이러한 영향들이 축적되어 생긴 결과가 바로 "광노화"이다. 이와 같은 피부의 광노화로 인해 표피와 진피조직이 변화하게 되면, 주름살이 생기고 피부가 누르스름해지며, 피부가 두꺼워지고 탄력성이 점차 감소하게 된다.In most people's growth, the skin responds easily to daylight, but as the age increases, the skin tissue gradually changes, making it difficult to respond to daylight, causing wrinkles, thickening of the skin, sagging skin, loss of skin elasticity, Skin roughness, skin dryness, and skin stains may occur. The result of the accumulation of these effects of sunlight is "photoaging". When the epidermis and dermal tissue changes due to photoaging of the skin, wrinkles are formed, the skin becomes yellowish, the skin becomes thicker and elasticity gradually decreases.
이러한 피부노화에 관한 문제점을 해결하기 위해 레티노이드(비타민 A)를 이용한 사례가 미국 특허공보 4603146, 4877805 등에 개시되어 있다.Examples of using retinoid (vitamin A) to solve the problem related to skin aging are disclosed in US Patent Publication No. 4603146, 4877805 and the like.
피부보호 화장료에 사용되는 레티노이드에는 레티놀(Retinol: Vitamin Aalcohol), 레티날(Retinal: Vitamin A aldehyde), 레티닐 에스테르의 일종인 레티닐 아세테이트(Retinyl acetate), 레티닐 프로피오네이트(Retnyl propionate), 레티닐 리놀리에이트(Retinyl linoleate) 및 레티닐 팔미테이트(Retinyl palmitate) 등이 있다. 이들중 레티놀은 인체에 자연적으로 존재하는 내인성 화합물로서 상피 조직의 분화와 성장에 필수적인 물질이다. 또한, 레티놀은 레티노익 애씨드(Retinoic acid) 등의 레티노이드에 비해 매우 높은 안전성을 가지고 있어서 피부개선 화장료의 원료로서 매우 적합하다고 할 수 있다.Retinoids used in skin care cosmetics include Retinol: Vitamin Aalcohol, Retinal: Vitamin A aldehyde, Retinyl acetate, Retinyl propionate, Retinyl linoleate and Retinyl palmitate. Of these, retinol is an endogenous compound that exists naturally in the human body and is essential for the differentiation and growth of epithelial tissue. In addition, retinol has very high safety compared to retinoids such as retinoic acid, and thus can be said to be very suitable as a raw material for skin improvement cosmetics.
최근들어 상기 레티노이드(retinoid)를 함유한 피부보호제에 대한 관심이 점차 증대되고 있는데, 예를 들어 비타민 A인 레티놀의 경우 여드름의 치료효과가 높아 피부연고제 형태의 많은 제품들이 생산되어 일반 소비자들이 쉽게 구입하여 사용하고 있는 상황이다. 게다가 최근에는 레티놀이 여드름 치유효과 뿐만 아니라 다른 광범위한 효능을 가지고 있음이 밝혀져 이를 응용하려는 노력이 시도되고 있다. 이와 같은 효능중 대표적인 것으로는 광노화 방지 및 일광에 손상된 피부의 치료 효능을 들 수 있다.Recently, there is a growing interest in skin protection agents containing retinoids. For example, retinol, a vitamin A, has a high therapeutic effect on acne, so many products in the form of skin ointments are produced and easily purchased by the general consumer. The situation is using. In addition, retinol has recently been found to have a wide range of effects as well as healing acne has been tried to apply it. Representative of such effects include the prevention of photoaging and the treatment of skin damaged by sunlight.
그러나, 레티놀은 피부주름 개선 및 방지효과, 여드름 치유효과가 매우 우수함에도 불구하고 제품에 처방될 경우 변색, 변취 현상이 발생하고, 시간이 지남에 따라 역가가 떨어져 효과가 감소하며, 소량 사용 시에도 피부자극이 유발되는 등의 문제점들로 인하여 화장료에서 이의 사용이 극히 제한되어 왔었다.However, although retinol is very effective in improving and preventing skin wrinkles and healing acne, discoloration and discoloration occur when prescribed in the product, and the effect decreases over time, and the effect decreases even when a small amount is used. Due to problems such as skin irritation, its use has been extremely limited in cosmetics.
따라서, 화장료에 레티놀과 함께 다른 성분을 첨가함으로써 레티놀이 가지고 있는 상기와 같은 문제점들을 해결하고자 하는 시도들이 많이 있어왔는데, 지금까지 이렇게 레티놀을 안정화시키기 위해 다른 물질이 첨가된 사례들을 살펴보면, 유용성 산화제인 BHT, dl-α-토코페롤 및 킬레이트제인 EDTA와 함께 레티노익 애씨드를 함유시켜 안정화 시킨 수중유(O/W)형 유화제형에 대한 특허(미국특허 3,906,108)가 있고, 유용성산화제인 토코페롤과, 구연산을 사용하여 레티놀을 안정화시킨 수중유형 유화제형의 특허(미국특허 4,247,547)가 있으며, 유용성 산화제인 BHT, BHA를 사용하여 레티놀, 레티닐아세테이트, 레티닐 팔미테이트를 함유시켜 안정화 시킨 유중수형 유화제형의 특허(미국특허 4,826,828)가 있고, 레티놀을 항산화제인 BHA, 아스코르빅 애씨드, 토코페릴리놀레에이트를 사용하여 안정화시킨 유중수형 특허(미국특허 4,720,353)가 있으며, 레티노이드의 화학적 안정성을 향상시키기 위해 한 종류 이상의 수용성 항산화제, 한 종류 이상의 유용성 항산화제, 및 킬레이트제를 함유시킨 수중유형 유화조성물(유럽특허 0440,398 BI)이 발표된 바 있고, 유럽특허1568106A1에서는 레티노이드를 안정화시키는 시스템으로 킬레이트제와 유용성 항산화제, 킬레이트제와 수용성 항산화제, 유화물의 유상과 수상에 동시에 존재하는 항산화제 및 자유염기형의 이미다졸을 함유하는 수중유형의 유화조성물이 보고된 바도 있다.Therefore, there have been many attempts to solve the above problems with retinol by adding other ingredients with retinol in cosmetics. So far, examples of adding other substances to stabilize the retinol are useful oxidizing agents. There is a patent for the oil-in-water (O / W) emulsifier type stabilized by containing Retinoic acid with BHT, dl-α-tocopherol and EDTA chelating agent (US Pat. No. 3,906,108). There is a patent for oil-in-water emulsifier type (US Patent 4,247,547) that stabilizes the retinol by using the oil-in-water type emulsifier type that is stabilized by containing retinol, retinyl acetate, retinyl palmitate using oil-soluble oxidizing agents BHT and BHA. (US Pat. No. 4,826,828) and retinol as antioxidants BHA, ascorbic acid, tocopheryl There is a water-in-oil type patent (US Pat. No. 4,720,353) stabilized using nooleate, and an oil-in-water emulsion containing at least one water-soluble antioxidant, at least one oil-soluble antioxidant, and a chelating agent to improve the chemical stability of the retinoid. (European Patent 0440,398 BI) has been published, European Patent 1568106A1 is a system for stabilizing retinoids, chelating and oil-soluble antioxidants, chelating and water-soluble antioxidants, antioxidants present in the oil phase and water phase of the emulsion and An oil-in-water emulsion composition containing free base imidazole has been reported.
상기의 여러가지 특허를 살펴보면, 유화형태에 따라 유,수용성 항산화제 및 킬레이트제의 종류를 변화시킴으로써 레티놀 및 이의 유도체를 안정화 시키고자 했던 것을 알 수 있다.Looking at the various patents, it can be seen that the purpose of stabilizing the retinol and its derivatives by changing the type of oil-soluble antioxidants and chelating agents according to the emulsification form.
본 발명자들은 상기와 같은 문제점들을 해결하기 위하여 많은 연구와 노력을 기울인 결과, 종래의 불안정한 고기능성 유용성 활성 물질을 2중으로 안정화시킴으로써 고기능성 효과를 오래 유지시키는 화장료 조성물을 개발하여 특허출원한 바 있다.(국내 특허출원 97-47262,47276)The present inventors have made a lot of research and efforts to solve the above problems, as a result of the patent application to develop a cosmetic composition that maintains a high functional effect for a long time by stabilizing a double unstable high functional useful active material in the prior art. (Domestic Patent Application 97-47262,47276)
한편, 현재 레티놀을 포함한 AHA, 비타민 C 등 화장료로서 개발되어 있는 대부분의 성분들은 상기와 같은 안전성 및 안정성 문제 이외에도 임상적 효능효과의 미약, 가시적 임상결과에 필요한 사용기간의 장기화 등의 문제점들을 가지고 있다. 이중에서도 특히 레티놀은 광노화에 의한 피부 진피층 콜라겐 다발(bundle)의 붕괴에 따른 피부탄력 감소 및 주름형성에 대해 외관상 굵은 주름을 매우 효과적으로 개선시키는 효능를 가지고 있으나, 콜라겐 다발구조(bundle structure), 피부탄력 및 미세주름은 거의 개선시키지 못하며, 이로 인해 레티놀 사용에 의한 주름개선에 요구되는 시간이 장기화될 수밖에 없는 실정이다.Meanwhile, most of the ingredients currently developed as cosmetics such as AHA and vitamin C, including retinol, have problems such as weak clinical efficacy effects and prolonged period of use required for visible clinical results, in addition to the safety and stability problems described above. . In particular, retinol has the effect of effectively improving the appearance of thick wrinkles against the reduction of skin elasticity and wrinkle formation caused by the collapse of the collagen bundle of skin dermis due to photoaging, but the collagen bundle structure, skin elasticity and Fine wrinkles are hardly improved, and thus, the time required for wrinkle improvement by using retinol is inevitably prolonged.
본 발명의 목적은 레티놀이 가지고 있는 기존의 효과는 향상시키고 레티놀이 함유된 화장료의 문제점은 개선하고자 하는 것이다. 구체적으로, 본 발명의 목적은 피부 주름 개선, 기미, 주근깨, 검버섯 등 색소침착의 개선, 피부 탄력 증진, 미백효과 및 보습효과 등 레티놀의 화장료로서의 효능은 그대로 가지고 있으면서도 임상적 효능효과의 미약, 가시적 임상결과에 필요한 사용기간의 장기화 등의 문제점이 극복된 화장료 조성물을 제공하고자 하는 것이다.An object of the present invention is to improve the existing effects of retinol and to improve the problems of cosmetics containing retinol. Specifically, the purpose of the present invention is to improve the skin wrinkles, blemishes, freckles, such as pigmentation, pigmentation improvement, skin elasticity enhancement, whitening effect and moisturizing effect, etc., while retaining the efficacy of the retinol as a cosmetic, weak and visible clinical efficacy It is to provide a cosmetic composition that overcomes problems such as prolongation of the period of use necessary for clinical results.
이와 같은 목적을 달성하기 위하여 본 발명은 기존 피부개선 성분으로써 광노화에 의한 깊은주름(외관상 주름) 개선 효과가 있는 레티놀과 함께 레티놀과는달리 잔주름(미세 주름) 개선효과를 가지고 있어 주름감소 및 피부탄력 증진 효과를 가지게 되는 우솔릭산(Ursolic acid)을 함유하는 화장료 조성물을 제공하는 것으로 수행된다.In order to achieve the above object, the present invention has the effect of improving the fine wrinkles (fine wrinkles) unlike the retinol together with the retinol having the effect of improving the deep wrinkles (appearing wrinkles) by photoaging as an existing skin improvement component. It is carried out to provide a cosmetic composition containing ursolic acid that will have an enhancing effect.
본 발명은 레티놀과 함께 우솔릭산(Ursolic acid)을 함유함으로써, 레티놀의 피부미용 효과가 향상되고 레티놀이 가지고 있는 화장료로서의 문제점이 개선된 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing ursolic acid together with retinol, thereby improving the skin beauty effect of retinol and improving the problem as a cosmetic having retinol.
본 발명자들은 우솔릭산(Ursolic acid)이 여드름 치료, 피부 주름 개선, 항산화 효과에 의한 피부 노화의 방지, 기미, 주근깨, 검버섯 등 색소침착의 개선, 손상피부의 치료, 자외선 차단 등을 위해 치료용 외용제 및 화장료에 널리 사용되고 있는 레티놀의 효과를 현저하게 향상시키고, 레티놀이 가지는 임상적 효능효과의 미약, 가시적 임상결과에 필요한 사용기간의 장기화 등 문제점들을 효과적으로 개선시킬 수 있음을 발견하여 본 발명을 완성하였다.The present inventors are ursolic acid (Ursolic acid) treatment for acne, skin wrinkle improvement, prevention of skin aging by the antioxidant effect, improvement of pigmentation such as blemishes, freckles, black mushrooms, treatment of damaged skin, sun protection, etc. The present invention has been found to significantly improve the effects of retinol, which is widely used in cosmetics, and to effectively solve problems such as weak clinical efficacy and prolonged period of use required for visible clinical results. .
본 발명에 사용된 우솔릭산[Ursolic acid((3β)-3-Hydroxyurs-12-en-28-oic acid), C30H48O3: 분자량456.68]은 Urson, Prunol, Micromrol, malol 등으로 알려져 있으며, 채소류, 약초등에 함유되어 있는 Pentacyclic triterpenoid 복합체로서 광노화된 피부의 개선(주름개선, 탄력증진) 및 항염증 효과가 우수하다(JP09143050, 09118611,1997.)고 알려져 있는 물질이다.Ursolic acid ((3β) -3-Hydroxyurs-12-en-28-oic acid), C 30 H 48 O 3 : molecular weight 456.68] used in the present invention is known as Urson, Prunol, Micromrol, malol, etc. It is a pentacyclic triterpenoid complex contained in vegetables, herbs, etc., and is known to be excellent in photoaging skin improvement (wrinkle improvement, elasticity improvement) and anti-inflammatory effect (JP09143050, 09118611,1997.).
대부분의 Triterpenoids 류와 마찬가지로 Ursolic acid도 식물에 널리 편재되어 있으며 동질이성질체인 Oleanolic acid[(3β)-3-Hydroxyolean-12-en-28-oic acid]을 포함하여 다양한 유도체들이 존재한다. 특히 Ursolic acid는 Oleanolic acid가 가지고 있는 항암(피부암), 항염, 항궤양, 간기능보호, 항균 효과 등과 동등한 약리효과를 가지고 있어 민간의학 분야에서는 오래전부터 사용되고 있는 물질이다. 화장료로의 Ursolic acid의 발견은 사과, 배, 덩굴월귤(Cranberries), 자두와 같은 과일 표면의 왁스(Wax) 코팅 성분으로부터 분리됨으로써 시작되었다.Ursolic acid, like most triterpenoids, is widely distributed in plants and contains various derivatives, including the isomeric oleanolic acid [(3β) -3-Hydroxyolean-12-en-28-oic acid]. Ursolic acid, in particular, has the same pharmacological effects as the anti-cancer (skin cancer), anti-inflammatory, anti-ulcer, hepatoprotective, and antibacterial effects of Oleanolic acid. The discovery of ursolic acid in cosmetics began by separating it from the wax coating components on the fruit's surface, such as apples, pears, cranberries, and plums.
이와 같은 Ursolic acid를 함유하고 있는 식물류로는Lamiaceae과(Family)가 대표적으로Rosemarinus officinalisL.,Lavendula augustifoliaMill.,Oreganum vulgareL.,Thymus vulgareL. 등에 다량 함유되어 있는 것으로 알려져 있다.Plants containing such ursolic acid are known to contain a large amount of Lamiaceae family, such as Rosemarinus officinalis L., Lavendula augustifolia Mill., Oreganum vulgare L., Thymus vulgare L.
본 발명의 화장료 조성물은 그 제형에 있어서 특별히 한정되는 바가 없는데, 예를 들면, 유연화장수, 수렴화장수, 영양화장수, 아이크림, 영양크림, 맛사지크림, 클렌징크림, 클렌징폼, 클렌징워터, 파우더, 엣센스, 팩 등의 제형을 가질 수 있다.The cosmetic composition of the present invention is not particularly limited in the formulation, for example, softening longevity, astringent longevity, nourishing longevity, eye cream, nutrition cream, massage cream, cleansing cream, cleansing foam, cleansing water, powder, essence It may have a dosage form, such as a pack.
또한, 각 제형의 화장료 조성물에 있어서, 상기한 레티놀 및 우솔릭산(Ursolic acid)을 포함하여 피부개선 원료로써 레티놀 및 우솔릭산(Ursolic acid) 이외의 성분들을 화장료의 제형 또는 사용목적 등에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있다.In addition, in the cosmetic composition of each formulation, it is difficult for those skilled in the art to include ingredients other than retinol and ursolic acid as skin raw materials including retinol and ursolic acid as described above. It can be selected and formulated without any enemy.
본 발명의 화장료 조성물에서 레티놀은 화장료 총중량에 대하여 0.001∼10.0중량%, 바람직하게는 0.05∼2.0중량%의 양으로 함유되며,, 우솔릭산(Ursolic acid)은 화장료 총중량에 대하여 0.01∼5.0중량%, 바람직하게는 0.1∼2.0 중량%의 양으로 함유된다.Retinol in the cosmetic composition of the present invention is contained in an amount of 0.001 to 10.0% by weight, preferably 0.05 to 2.0% by weight relative to the total weight of the cosmetic, Ursolic acid is 0.01 to 5.0% by weight relative to the total weight of the cosmetic, Preferably it is contained in the amount of 0.1-2.0 weight%.
이하, 시험예를 들어 본 발명의 구성 및 효과를 상세히 설명하고자 하나, 본 발명을 이들 시험예에 한정하고자 하는 것은 아니다Hereinafter, a test example will be described in detail the configuration and effects of the present invention, but the present invention is not intended to be limited to these test examples.
시험예를 위하여 하기 표 1과 같이 본 발명에 따라 레티놀과 함께 우솔릭산(Ursolic acid)을 함유하는 조성물(실시예) 및 레티놀 만을 함유하는 조성물(비교실시예)이 제조되었다.For the test examples, according to the present invention as shown in Table 1, a composition containing ursolic acid together with retinol (example) and a composition containing only retinol (comparative example) were prepared.
하기 표 1의 A상과 B상의 원료를 각각 균일하게 혼합, 75℃까지 가열시킨 후, 두 상을 유화시키고, 45℃까지 냉각한 후 안정화한 레티놀(리포스피어), 우솔릭산(Ursolic acid) 및 향과 방부제를 차례로 첨가, 혼합하여 최종 제품으로 하였다.The raw materials of phase A and phase B of Table 1 were uniformly mixed, heated to 75 ° C., and then emulsified in two phases, cooled to 45 ° C., and then stabilized retinol (liposphere), ursolic acid, and The fragrance and the preservative were added and mixed in order to obtain the final product.
표 1.Table 1.
실시예 및 비교실시예Examples and Comparative Examples
레티놀은 상기 표 1의 리포스피아에 함유되는데, 리포스피아는 하기 표 2의 조성으로서 A상을 균일하게 혼합, 용해시킨 후 B상에 첨가하고 유화시켜 최종 제품으로 한다.Retinol is contained in the liposperia of Table 1, which is added to the B phase and then emulsified as a final product.
표 2.Table 2.
리포스피아의 성분Liposperia Ingredients
[시험예 1] 피부주름개선효과[Test Example 1] Wrinkle improvement effect
상기 본 발명의 레티놀 및 우솔릭산(Ursolic acid)을 함유하는 화장료에 대한 피부주름 개선 효과를 측정하였다.The skin wrinkle improvement effect on the cosmetics containing the retinol and ursolic acid of the present invention was measured.
30세 이상의 여성 20명(평균연령 33.5세)을 2그룹(A,B)으로 나누어 A그룹을 대상으로는 실시예를, B그룹을 대상으로는 비교실시예를 각각 상기 표 1에 따라 제형하여 팔의 상박 2X2 ㎠의 면적에(2회/일, 0.2g/회) 8주 및 24주간 도포한 후, 투명한 실리콘 재질의 용액을 이용하여 피부주름의 레플리카(Replica)를 떠서 피부주름측정기(SKIN VISIOMETER SV400, C+K Electronics GmbH. Germany)로 피부주름변화를 측정하였다. 레플리카의 상을 CCD 카메라로 3차원적 분석하고, 각각의 주름의 거칠기(Rm: m은 1 이상의 정수)의 합을 주름의 개수로 나눈 값인 하기 식의 평균주름거칠기(Rz)로 주름개선효과를 분석하였다. 시험결과는 하기 표3 및 표4에 나타내었다.Twenty women over 30 years old (average age 33.5 years) were divided into two groups (A and B), and the examples for group A and the comparative examples for group B were formulated according to Table 1 above. After 8 weeks and 24 weeks of application on the area of 2X2 cm2 of the upper arm (2 times / day, 0.2g / time), a replica of the skin wrinkles is floated using a transparent silicone solution. Skin wrinkle change was measured using VISIOMETER SV400, C + K Electronics GmbH. Three-dimensional analysis of the image of the replica with a CCD camera, wrinkle improvement by the average wrinkle roughness (R z ) of the formula obtained by dividing the sum of roughness (R m : m is an integer of 1 or more) of each wrinkle by the number of wrinkles The effect was analyzed. The test results are shown in Tables 3 and 4 below.
표 3.Table 3.
피부주름개선효과(8주)Skin wrinkle improvement effect (8 weeks)
표 4.Table 4.
피부주름개선효과(24주)Skin wrinkle improvement (24 weeks)
시험 결과, 8주 후 레티놀과 우솔릭산(Ursolic acid)을 함유한 실시예는 31.2㎛ 낮아져(p<0.05) 우솔릭산(Ursolic acid) 만을 함유한 비교실시예에 비해 약 69.6% 이상 주름이 더 개선되었다. 따라서 위의 결과로부터 우솔릭산(Ursolic acid)이 레티놀의 주름개선효과를 매우 효과적으로 상승시킴을 알 수 있다.As a result, after 8 weeks, the examples containing retinol and ursolic acid were lowered by 31.2 μm (p <0.05), and the wrinkles were improved more than about 69.6% compared to the comparative examples containing only ursolic acid. It became. Therefore, it can be seen from the above results that solic acid (Ursolic acid) very effectively enhances the wrinkle improvement effect of retinol.
아울러 표 4의 피부주름 개선효과(24주)를 보면, 본 발명의 실시예는 85.4㎛ 낮아져(p<0.01) 매우 유효한 주름개선효과를 보이고 있다. 반면, 비교실시예는 43.8 ㎛ 낮아져(p<0.05) 주름개선효과는 있으나 주름개선효과가 표 3의 실시예의 피부주름 개선효과(8주) 시험 결과와 유사함을 알 수 있다. 이는 일반적으로 현재 주름개선용으로 사용되는 화장료들이 가시적인 효과를 보이는데 24주 이상의 장시간이 걸리는데 비해 본 발명의 우솔릭산 함유 화장료 조성물은 아주 짧은 단시간 안에 가시적인 효과를 볼 수 있음을 보여주고 있다.In addition, looking at the skin wrinkle improvement effect (24 weeks) of Table 4, the embodiment of the present invention is 85.4㎛ lower (p <0.01) shows a very effective wrinkle improvement effect. On the other hand, the comparative example is 43.8 μm lower (p <0.05), but the wrinkle improvement effect, but it can be seen that the wrinkle improvement effect is similar to the results of the skin wrinkle improvement effect (8 weeks) of the Example of Table 3. This generally shows that the cosmetics currently used for wrinkle improvement may take a long time of more than 24 weeks to show a visible effect, whereas the ursolic acid-containing cosmetic composition of the present invention can see a visible effect in a very short time.
[시험예 2] 피부주름개선의 임상효과Test Example 2 Clinical Effect of Skin Wrinkle Improvement
상기 본 발명의 레티놀 및 우솔릭산(Ursolic acid)을 함유하는 화장료 대한 피부주름개선 임상효과를 측정하였다.The clinical effects of skin wrinkle improvement on the cosmetics containing the retinol and ursolic acid of the present invention were measured.
30세 이상의 여성 20명(평균연령 33.5세)을 2그룹으로 나누고, A그룹에는 실시예를, B그룹에는 비교실시예를, 각각 상기 표 1에 따라 제형하여 주름이 있는 눈가를 중심으로 12주간 도포한 후, 숙련자의 객관적 평가와 피검자의 주관적 평가를 다음의 6등급으로 분류하여 평가함으로써 피부주름의 개선정도(ΔW)를 측정하였다. 결과는 하기 표 5와 표 6에 나타내었다.Twenty women over 30 years old (mean age 33.5 years old) were divided into two groups. Examples were prepared in Group A and Comparative Examples in Group B, respectively. After application, the degree of improvement of skin wrinkle (ΔW) was measured by classifying the objective evaluation of the skilled person and the subjective evaluation of the subject into the following six grades. The results are shown in Tables 5 and 6 below.
·피부주름개선 평가 기준 :Skin wrinkle improvement evaluation criteria:
-3: 극히 심하게 악화 -2: 악화 -1: 약간 악화-3: extremely badly -2: worsening -1: slightly worsening
0: 변화없음 1: 약간 개선 2: 개선 3: 매우 개선0: no change 1: slightly improved 2: improved 3: highly improved
표 5.Table 5.
피부주름개선 임상효과 (숙련자의 객관적 평가)Clinical Effects of Skin Wrinkle Improvement (Objective Evaluation by Skilled Workers)
표 6.Table 6.
피부주름개선 임상효과 (피검자의 주관적 평가)Clinical effect of skin wrinkle improvement (subjective evaluation of subject)
임상 시험 결과 실시예의 경우 숙련자의 객관적 평가와 피검자의 주관적 평가가 각각 2.7, 2.8로 주름개선 효과가 매우 우수함을 알 수 있다. 이는 레티놀 만을 함유한 비교실시예에 비해 숙련자의 객관적 평가와 피검자의 주관적 평가가 각각 42.1%, 40% 증가한 것으로, 우솔릭산(Ursolic acid)이 레티놀의 주름개선효과를 매우 효과적으로 증진시킴을 알 수 있다.In the case of the clinical trial results, the objective evaluation of the skilled person and the subjective evaluation of the subject were 2.7 and 2.8, respectively, indicating that the wrinkle improvement effect was very excellent. This is a 42.1% and 40% increase in the objective evaluation and the subjective evaluation of the subjects, respectively, compared to the comparative example containing only retinol, and it can be seen that ursolic acid greatly enhances the wrinkle improvement effect of retinol. .
[시험예 3] 피부탄력개선의 임상효과Test Example 3 Clinical Effect of Skin Elasticity Improvement
상기 본 발명의 레티놀 및 우솔릭산(Ursolic acid)을 함유하는 화장료에 대한 피부탄력 개선 임상효과를 측정하였다.The clinical effect of improving skin elasticity on the cosmetics containing the retinol and ursolic acid of the present invention was measured.
건강한 여성 20명(평균연령 33.5세)을 대상으로 실시예와 비교실시예를 상기 표 1에 따라 제형하여 눈가를 중심으로 왼쪽에는 실시예를 오른쪽에는 비교실시예를 12주간 도포한 후, 피부탄력측정기(Cutometer SEM 575, C+K Electronic Co., Germany)를 이용하여 피부탄력을 측정하였다. 시험 결과는 하기 표 7에 Cutometer SEM 575의 △R8 값으로 기재하였는데, R8 값은 피부 점탄성(viscoelasticity)의 성질을 나타낸다.20 healthy women (mean age 33.5 years) were formulated according to the Examples and Comparative Examples according to Table 1 above, and applied to the Examples on the left side and the Comparative Example on the right for 12 weeks, the skin elasticity Skin elasticity was measured using a measuring instrument (Cutometer SEM 575, C + K Electronic Co., Germany). The test results are described in Table 7 below as the ΔR8 value of the Cutometer SEM 575, where the R8 value represents the nature of the skin viscoelasticity.
표 7.Table 7.
피부탄력Skin elasticity
표 7 의 결과에서 알 수 있듯이 우솔릭산(Ursolic acid)을 함유한 실시예의 피부탄력은 비교실시예에 비해 217% 증가했다. 이를 볼 때, 레티놀이 콜라겐의 합성을 촉진시켜 피부의 탄력을 증진시키는데 우솔릭산(Ursolic acid)이 매우 효과적으로 상승효과를 가져다줌을 알 수 있다. 이는 우솔릭산(Ursolic acid)의 콜라겐 합성능에 의하여 콜라겐의 다발구조가 정상적으로 이루어지고, 이로인해 피부의 탄력이 촉진됨으로써 피부탄력이 급격하게 증가되는 것으로 볼 수 있다.As can be seen from the results of Table 7, the skin elasticity of the example containing ursolic acid was increased by 217% compared to the comparative example. This suggests that ursolic acid has a very effective synergistic effect in promoting retinol collagen synthesis to promote skin elasticity. It can be seen that the bundle structure of collagen is normally made by the collagen synthesis ability of ursolic acid, and thus the skin elasticity is rapidly increased by promoting the elasticity of the skin.
[시험예 4] 보습효과Test Example 4 Moisturizing Effect
상기 본 발명의 레티놀 및 우솔릭산(Ursolic acid)을 함유하는 화장료에 대한 보습효과를 측정하였다.The moisturizing effect on the cosmetics containing the retinol and ursolic acid of the present invention was measured.
25℃, 상대습도 45%, 공기의 흐름이 없는 실내에서 건강한 여성 20명(평균연령 33.5세)을 대상으로 실시예와 비교실시예를 각각 상기 표 1에 따라 제형하여 팔의 상박에 하루에 3회 6주간 도포한 후, TEWAMETER TM210(C+K electronic GmbH. Germany)를 이용하여 경피수분손실량 즉, TEWL(Transepidermal Water Loss)값을 시간 변화에 따른 TEWL 값 변화량 △TEWL로 측정하고, CORNEOMETER CM 820 PC(C+K electronic GmbH. Germany)를 이용하여 표피 수분량에 따른 전기전도도의 변화로 0에서 150까지 피부의 수분량을 수치화하여 보습효과를 측정하였다. 시험결과는 하기 표 8에 나타내었다.Example 25 and comparative examples of 20 healthy women (average age 33.5 years) indoors without air flow at 25 ℃, the Examples and Comparative Examples were formulated in accordance with Table 1, respectively, 3 to the upper arm After 6 weeks of application, the transdermal moisture loss, that is, the TEWL (Transepidermal Water Loss) value, was measured using TEWAMETER TM210 (C + K electronic GmbH. Moisturizing effect was measured by quantifying the moisture content of the skin from 0 to 150 with the change of the electrical conductivity according to the epidermal moisture content using a PC (C + K electronic GmbH. Germany). The test results are shown in Table 8 below.
표 8.Table 8.
피부보습효과Skin moisturizing effect
시험 결과, 실시예의 △TEWL 값은 5.8g/hm2로 비교실시예에 비해 경피수분손실량이 6주 후 매우 효과적으로 개선되었음을 알 수 있다.As a result, it can be seen that the ΔTEWL value of the Example was 5.8 g / hm 2 , and the percutaneous moisture loss amount was improved very effectively after 6 weeks compared to the comparative example.
아울러 피부의 수분량을 측정한 Corneometer value에서도 실시예가 비교실시예에 비해 21.8% 증가하여 피부가 매우 촉촉해짐을 알 수 있다..In addition, in the Corneometer value measured the moisture content of the skin, the Example is increased by 21.8% compared to the Comparative Example it can be seen that the skin is very moist.
[시험예 5] 피부 안전성 시험Test Example 5 Skin Safety Test
상기 본 발명의 레티놀 및 우솔릭산(Ursolic acid)을 함유하는 화장료에 대한 피부 안전성 시험을 실시하였다.Skin safety test was performed on the cosmetics containing the retinol and ursolic acid of the present invention.
피검자 30명(평균연령 26.7세 , 연령분포 18세-30세)을 2그룹(A,B)으로 나누어 A그룹을 대상으로는 실시예를, B그룹을 대상으로는 비교실시예를 각각 상기표 1에 따라 제형하여 Haye's Test Chamber를 이용 상박에 피부 첩포시험(Patch Test)을 실시하였다. 단 건선(Psoriasis), 습진(Eczema), 기타 피부병변 보유자나 임신, 수유부 또는 피임제, 항히스타민제 등을 복용하고 있는 사람은 본 시험에서 제외 하였다.Thirty subjects (mean age 26.7 years, age distribution 18 years to 30 years) were divided into two groups (A, B), and the examples for group A and the comparative examples for group B, respectively. Formulated according to 1, using a Haye's Test Chamber to the skin patch test (Patch Test) was performed. Those with Psoriasis, Eczema, and other skin lesions or those who are pregnant, nursing or contraceptives, and antihistamines are excluded from this study.
시험부위를 70% 에탄올로 닦아낸 뒤 건조시키고, A그룹에는 실시예를, B그룹에는 비교실시예를 각각 15㎍씩 Chamber에 적하 시킨 후, 시험 부위인 상박 부위에 얹어 고정시킨다. 첩포는 24시간 동안 도포하고 첩포를 제거한 후에는 Marking Pen으로 시험부위를 표시하여 각각 24시간, 48시간, 72시간 후에 시험부위를 관찰한다.The test site was wiped with 70% ethanol and dried, and the Examples were dropped into the A group and the Comparative Examples were dropped into the chamber of 15 µg each in the B group, and then fixed on the upper arm, which is the test site. The patch is applied for 24 hours, and after the patch is removed, the test site is marked with a marking pen, and the test site is observed after 24 hours, 48 hours, and 72 hours, respectively.
판정은 첩포 제거 24시간, 48시간, 72시간 후에 행하며 피부반응은 하기 표 9의 국제접촉피부염연구회(International Contact Dermatitis Research Group:ICDRG)의 규정에 따라 판정하였다. 시험결과는 하기 표 10에 나타내었다.Determination was performed 24 hours, 48 hours, 72 hours after patch removal, and skin reaction was determined according to the regulations of the International Contact Dermatitis Research Group (ICDRG) shown in Table 9 below. The test results are shown in Table 10 below.
표 9.Table 9.
국제접촉피부염연구회의 판정 기준Criteria for international contact dermatitis
표 10.Table 10.
피부 안전성Skin safety
피부안전성 시험 결과, 실시예는 평균 자극정도가 0으로 피부에 자극이 없는 안전한 화장료임을 알 수 있고, 비교실시예의 레티놀을 안정화한 리포스피아를 함유한 크림도 24시간 경과 후 약한 자극을 보였으나 거의 자극이 없어 일반적으로 레티놀이 피부에 자극을 갖고 있음을 상기할 때 본 발명의 리포스피어가 레티놀의 자극을 매우 효과적으로 완화시켜 줌을 알 수 있다.As a result of skin safety test, the Example shows that the average irritation degree is 0, and it is a safe cosmetic without irritation on the skin, and the cream containing lipopia which stabilized the retinol of Comparative Example also showed weak irritation after 24 hours. It can be seen that the liposphere of the present invention very effectively alleviates the retinol irritation when it is recalled that there is no irritation so that retinol generally has irritation to the skin.
[시험예 6] 피부자극감 시험(Stinging Potential Test)[Test Example 6] Skin irritation test (Stinging Potential Test)
상기 본 발명의 레티놀 및 우솔릭산(Ursolic acid)을 함유하는 화장료 대한 피부자극감 시험을 실시하였다.The skin irritation test was carried out on the cosmetics containing the retinol and ursolic acid of the present invention.
피검자 20명(평균연령 24세, 연령분포 20세-31세)을 대상으로 Steam Generator를 사용하여 15분간 충분히 Sweating 시킨 후, 왼쪽 얼굴에는 실시예를, 오른쪽 얼굴에는 비교실시예를 코 주위 및 뺨을 중심으로 강하게 비빈다. Stinging grade는 적용 후 자극 반응이 나타나는 시간에 따라 30초 이내에 나타나면 Intense stinging, 2.5분 이내는 mild stinging, 5분 이내는 moderate stinging, 8분 이내는 delayed stinging으로 분류하여 평가하였다. 단 건선(Psoriasis), 습진(Eczema), 기타 피부병변 보유자나 임신, 수유부 또는 피임제, 항히스타민제등을 복용하고 있는 사람은 본 시험에서 제외하였다.For 20 subjects (average age 24 years, age 20-31 years), a sufficient amount of sweating was performed using a steam generator for 15 minutes, followed by an example on the left face and a comparative example on the right face. Rubbing strongly around. Stinging grades were evaluated as classified as intense stinging within 30 seconds, mild stinging within 2.5 minutes, moderate stinging within 5 minutes, and delayed stinging within 8 minutes after application. Those with Psoriasis, Eczema, or other skin lesions, or those who are pregnant, nursing or contraceptives, and antihistamines are excluded from this study.
시료(실시예, 비교실시예)를 얼굴에 바른후 나타나는 피부반응(가려움, 따가움, 쓰라림, 붉어짐, 부어오름 등)을 8분 동안 관찰하고, 자극정도(Response score)를 피검자수(n)로 나누어 자극양성율(Response rate: %)을 구함으로써 자극을 평가하였다. 자극양성율에 따른 피부자극 정도는 하기 표 11에 따라 판정하고 그 결과를 표 12에 나타내었다.After applying the sample (Example, Comparative Example) to the face, the skin reaction (itch, itching, soreness, redness, swelling, etc.) observed for 8 minutes, and the response score to the number of subjects (n) Stimulation was evaluated by obtaining the response rate (%). The degree of skin irritation according to the stimulation rate was determined according to Table 11 below and the results are shown in Table 12.
표 11.Table 11.
피부자극감 시험 판정기준Skin irritation test criteria
표 12.Table 12.
피부자극감 시험 결과Skin irritation test result
피부자극감 시험에 의한 피부안전성 시험 결과 실시예는 Response rate(%)이 0.5로 무자극으로 판정되었으며, 레티놀 만을 함유한 비교실시예는 Response rate(%)이 0.9로 약간의 자극이 나타났다. 이는 일반적으로 레티놀을 함유한 크림이 갖고 있는 자극에 비해 매우 낮은 정도로써, 리포스피어에 의해 레티놀에 의한 피부자극이 현저히 완화됨을 알 수 있다.As a result of skin safety test by skin irritation test, the Example was determined to be non-irritating with a response rate (%) of 0.5, and the comparative example containing only retinol showed slight irritation with a response rate (%) of 0.9. This is generally very low compared to the irritation of the cream containing retinol, it can be seen that the skin irritation caused by retinol is remarkably relieved by liposphere.
[시험예 7] 제형의 안정성 시험Test Example 7 Stability Test of Formulation
상기 본 발명의 레티놀 및 우솔릭산(Ursolic acid)을 함유하는 화장료 대한 제형의 안정성 시험을 실시하였다.The stability test of the formulation for the cosmetic containing the retinol and ursolic acid of the present invention was carried out.
화장료의 안정성을 시험하기 위해 상기 실시예, 비교실시예를 45℃로 일정하게 유지되는 항온조에서 불투명 초자 용기에 담아 12주동안 보관하고, 또한 4℃로 일정하게 유지되는 완전히 차광된 냉장고 내에서 불투명 초자 용기에 담아 12주 동안 보관한 후, 분리 정도 및 변색 정도를 비교 측정하였다. 그 결과를 하기 표 13에 나타내었다. 이때 제품 분리 및 변색 정도를 다음의 6등급으로 분류하여 평가하였다.To test the stability of the cosmetics, the above examples and comparative examples were kept in an opaque glass container in a constant temperature bath at 45 ° C. for 12 weeks, and were also opaque in a completely shaded refrigerator kept at 4 ° C. After storing for 12 weeks in a glass container, the degree of separation and discoloration were measured. The results are shown in Table 13 below. At this time, the degree of product separation and discoloration were evaluated by classifying into the following six grades.
·제품 변색 평가 기준 :Product discoloration evaluation criteria:
0: 변화 없음 1: 극히 조금 분리(변색)0: no change 1: very little separation (discoloration)
2: 조금 분리(변색) 3: 조금 심하게 분리(변색)2: Separate slightly (discolored) 3: Separate slightly (discolored)
4: 심하게 분리(변색) 5: 극히 심하게 분리(변색)4: severely separated (discolored) 5: extremely severely separated (discolored)
표 13.Table 13.
분리 및 변색정도Separation and discoloration
상기 표 13에서 알 수 있는 바와 같이, 실시예 및 비교실시예 모두 45℃에서 약간의 변색 증상이 있으나 이는 일반 크림 제형에서 나타날 수 있는 정도로 레티놀이 온도에 매우 민감한 물질임을 감안할 때 매우 안정한 제형임을 알 수 있다. 이로써 리포스피어에 의해 레티놀이 매우 효과적으로 안정화됨을 알 수 있다.As can be seen in Table 13, both Examples and Comparative Examples have a slight discoloration at 45 ℃ but this is a very stable formulation considering that the material is very sensitive to the retinol temperature that can appear in the general cream formulation Can be. This shows that retinol is very effectively stabilized by liposphere.
이하 상기한 시험예들의 결과를 근거로 하여 레티놀 및 우솔릭산(Ursolic acid)을 함유하는 화장료를 조성하여 제시한다. 그러나, 본 발명의 조성물을 하기의 제형예들로 한정하고자 하는 것은 아니다.Hereinafter, based on the results of the above test examples, a cosmetic composition containing retinol and ursolic acid is presented. However, the composition of the present invention is not intended to be limited to the following formulation examples.
제형예 1. 유연화장수(스킨로션)Formulation Example 1 Softening Cosmetic (Skin Lotion)
제형예 2. 영양화장수(밀크로션)Formulation Example 2. Nutrients (Milk Lotion)
제형예 3. 영양크림Formulation Example 3. Nutrition Cream
제형예 4. 마사지크림Formulation Example 4 Massage Cream
제형예 5. 팩Formulation Example 5 Pack
이상에서 살펴본 바와 같이 본 발명 화장료 조성물에 우솔릭산이 함유됨으로써 피부 주름 개선, 기미, 주근깨, 검버섯 등 색소침착의 개선, 피부 탄력 증진, 미백효과 및 보습효과 등 레티놀의 화장료로서의 효능은 그대로 가지고 있으면서도 임상적 효능효과의 미약, 가시적 임상결과에 필요한 사용기간의 장기화 등의 문제점이 극복된 화장료 조성물을 제공할 수 있게 되었다.As described above, the cosmetic composition of the present invention contains ursolic acid, thereby improving clinical wrinkles, improving blemishes, freckles, and pigments such as blotch, enhancing skin elasticity, whitening effect, and moisturizing effect, while maintaining the efficacy of retinol as a cosmetic. It is possible to provide a cosmetic composition that overcomes the problems of weak efficacy and prolonged period of use required for visible clinical results.
또한, 본 발명의 우솔릭산 함유 화장료 조성물은 피부자극을 발생시키지 않고 보관시 분리 또는 변색현상이 발생하지 않는 등 화장료로서의 안전성(Safety) 및 안정성(Stability)이 현저하게 개선된 것으로 밝혀졌다.In addition, the ursolic acid-containing cosmetic composition of the present invention was found to significantly improve the safety and stability as a cosmetic such as not causing skin irritation and no separation or discoloration phenomenon during storage.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990060763A KR20010057429A (en) | 1999-12-23 | 1999-12-23 | Skin care composition containing Ursolic acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990060763A KR20010057429A (en) | 1999-12-23 | 1999-12-23 | Skin care composition containing Ursolic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20010057429A true KR20010057429A (en) | 2001-07-04 |
Family
ID=19628467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990060763A Ceased KR20010057429A (en) | 1999-12-23 | 1999-12-23 | Skin care composition containing Ursolic acid |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20010057429A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100427777B1 (en) * | 2001-09-25 | 2004-04-28 | 엔프라니 주식회사 | Nanocapsulized ursolic acid and preparing method thereof |
US8084062B2 (en) | 2005-01-31 | 2011-12-27 | Amorepacific Corporation | Anti-aging cosmetic composition |
KR101155225B1 (en) * | 2009-02-27 | 2012-06-13 | (주)아모레퍼시픽 | Cosmetic composition for external application for skin whitening |
KR101155180B1 (en) * | 2009-02-27 | 2012-06-13 | (주)아모레퍼시픽 | Anti-aging sunscreen cosmetic composition for inhibiting neuronal cell damage by uv |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723139A (en) * | 1996-09-27 | 1998-03-03 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions containing a polycyclic triterpene carboxylic acid and a retinoid |
JPH115727A (en) * | 1997-06-17 | 1999-01-12 | Pola Chem Ind Inc | Skin cosmetic |
-
1999
- 1999-12-23 KR KR1019990060763A patent/KR20010057429A/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723139A (en) * | 1996-09-27 | 1998-03-03 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions containing a polycyclic triterpene carboxylic acid and a retinoid |
WO1998013019A1 (en) * | 1996-09-27 | 1998-04-02 | Unilever Plc | Skin care compositions containing an acid and a retinoid |
JPH115727A (en) * | 1997-06-17 | 1999-01-12 | Pola Chem Ind Inc | Skin cosmetic |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100427777B1 (en) * | 2001-09-25 | 2004-04-28 | 엔프라니 주식회사 | Nanocapsulized ursolic acid and preparing method thereof |
US8084062B2 (en) | 2005-01-31 | 2011-12-27 | Amorepacific Corporation | Anti-aging cosmetic composition |
KR101155225B1 (en) * | 2009-02-27 | 2012-06-13 | (주)아모레퍼시픽 | Cosmetic composition for external application for skin whitening |
KR101155180B1 (en) * | 2009-02-27 | 2012-06-13 | (주)아모레퍼시픽 | Anti-aging sunscreen cosmetic composition for inhibiting neuronal cell damage by uv |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101425031B1 (en) | Cosmetic composition for anti-irritation and skin moisturization containing Citrus junos Siebold seed oil and Mangifera Indica seed oil | |
Akhtar et al. | Evaluation of various functional skin parameters using a topical cream of Calendula officinalis extract | |
KR101382112B1 (en) | Composition of skin external application containing Chamaecyparis obtusa polysaccharide | |
JPH08119825A (en) | Hydroxytyrosol, application for skin external medicine or bathing agent | |
WO2008072941A1 (en) | Compositions comprising compounds of natural origin for damaged skin | |
KR101746639B1 (en) | Composition with skin lightening and moisturizing effects containing bee venom extracts | |
KR102227355B1 (en) | Complex cosmetic composition for non-irritating weak acid exfoliation and epithelial cell nutrition | |
KR101352363B1 (en) | Composition of skin external application for moisturizing comprising Scrophularia buergeriana Miq. extract | |
KR100501399B1 (en) | Cosmetic Compostion for Preventing Skin Aging Comprising Plant Extract as Oriental Medicine Stabilized in Nanoliposome | |
KR102142311B1 (en) | Skin external composition comprising tangeretin | |
KR100377397B1 (en) | Skin care composition containing retinol and epidermal growth factor | |
KR101574558B1 (en) | Cosmetic composition containing ginsenoside Rd, Rb2 and Bambusae Caulis in Taeniam extracts | |
KR102162377B1 (en) | Extracts derived from natural products and cosmetic composition containing the same, and process for producing the same | |
KR20080001031A (en) | Cosmetic composition for anti-wrinkle containing hawthorn extract | |
KR20050117958A (en) | Topical nano liposome formulation including extracted purified herbal mixture and whitening cosmetics using this formulation | |
KR101322850B1 (en) | The cosmetic composition for pore-minimizing and inhibition of Sebum Secretion containing the extract of leaves of Mentha arvensis var. piperascens, wheat bud, and Platycodon grandiflorum | |
KR100468434B1 (en) | Cosmetic Compositions Comprising Vitamin C or Derivatives thereof Areca catechu L extract for Preventing Skin Aging | |
KR101648466B1 (en) | Cosmetic composition for improving skin | |
KR20010057429A (en) | Skin care composition containing Ursolic acid | |
KR102333132B1 (en) | Cosmetic Composition containing Frangipani Oil or Fermented Frangipani Oil | |
JPH03200708A (en) | Dermal external agent | |
JPH1192332A (en) | Skin preparation composition for external use | |
KR100638053B1 (en) | Cosmetic composition for alleviating skin irritation containing Soru-Jin extract as an active ingredient | |
JPH09255551A (en) | Skin preparation for external use | |
KR20160000318A (en) | Cosmetic composition containing Fir tree oil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19991223 |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20041126 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19991223 Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060427 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20060630 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20060427 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |